The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...

In India, more than 100 cases have been reported with hallmarks of this rare neurological disease that can cause paralysis.India' s western city of Pune is battling rising cases of the Guillain-Barré ...

Guillain-Barré Syndrome (GBS) is a rare disorder in which the body’s immune system mistakenly attacks the peripheral nerves. This condition can lead to muscle weakness, paralysis, and a host of ...

Most recover, but early treatment is crucial. Infections and, rarely, vaccines can trigger GBS, making this spike notable. Guillain-Barre Syndrome (GBS) has hit Pune city as 26 cases have come to ...

Guillain-Barré Syndrome is an uncommon ... This association has led to questions about the safety of flu vaccines, although the risk of GBS from influenza vaccination is much lower than the ...

The neurologist explains the link between Guillain-Barre Syndrome and paralysis, and the initial symptoms to watch out for.

So far, 59 people in Pune have been diagnosed with Guillain-Barré Syndrome (GBS), a rare neurological ... the disorder is linked to the COVID-19 vaccine. In response, The Free Press Journal ...

Health News Live Updates: Get the latest on global health, emerging diseases, vaccine trials, and medical breakthroughs with real-time updates and expert insights. Health News Live Updates ...

Maharashtra reports a surge in Guillain-Barr Syndrome cases, with 163 confirmed so far should we be concerned about an outbreak? Meanwhile, Uganda has officially confirmed an Ebola outbreak ...

India's western city of Pune is battling rising cases of the Guillain-Barré Syndrome (GBS), with at ... This is because vaccines tend to have similar weak or inactive structures akin to the ...

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. To assess the risk of GBS with these vaccines, the FDA conducted a postmarketing ...